Foretinib (GSK1363089, XL880)

Catalog No. A10998

Foretinib (GSK1363089,XL880)是c-Met和VEGFR-2的多激酶抑制剂,可抑制增殖,诱导Anoikis并损害卵巢癌转移。
  • Hamzehlou S, .et al. Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells, Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
  • Hayato Ogura, .et al. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity, Sci Rep, 2017, 7: 5519 PMID: 28717217
  • Fuse MJ, .et al. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers, Mol Cancer Ther, 2017, Oct;16(10):2130-2143 PMID: 28751539
  • Ryohei Katayama, .et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer, Clin Cancer Res. , 2015, Jan 1; 21(1): 166–174. PMID: 25351743
Catalog Num A10998
M. Wt 632.7
Formula C34H34F2N4O6
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 849217-64-7
Synonyms GSK089, EXEL-2880
SMILES COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
Foretinib (GSK1363089,XL880)是c-Met和VEGFR-2的多激酶抑制剂,可抑制增殖,诱导Anoikis并损害卵巢癌转移。
Targets
Target Value
MetIC50: 0.4nM
KDRIC50: 0.86nM
Tie-2IC50: 1.1nM
VEGFR3/FLT4IC50: 2.8nM
RONIC50: 3nM
FLT3IC50: 3.6nM
PDGFRαIC50: 3.6nM
KitIC50: 6.7nM
VEGFR1/FLT1IC50: 6.8nM
PDGFRβIC50: 9.6nM
FGFR1IC50: 660nM
EGFRIC50: 2.99μM
In vitro (25°C) DMSO 87 mg/mL (137.51 mM)
Water Insoluble
Ethanol Insoluble
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 15.81 mL 79.03 mL 158.05 mL
0.5 mM 3.16 mL 15.81 mL 31.61 mL
1 mM 1.58 mL 7.9 mL 15.81 mL
5 mM 0.32 mL 1.58 mL 3.16 mL

*The above data is based on the productmolecular weight 632.7. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.